Navigation Links
Penn researchers help graft olfactory receptors onto nanotubes
Date:7/26/2011

ly what molecules are bound to them," Johnson said.

As the particular GPCR the team worked with was an olfactory receptor, the test case for their nanotube device was to function as sensor for airborne chemicals.

"If there's something in the atmosphere that wants to bind to this molecule, the signal we get through the nanotube is about what fraction of the time is something bound or not. That means we can get a contiguous read out that's indicative of the concentration of the molecule in the air," Johnson said.

While one could imagine scaling up these nanotube devices into a synthetic nose making one for each of the approximately 350 olfactory GPCRs in a human nose, or the 1,000 found in a dog's Johnson thinks that medical applications are much closer to being realized.

"GPCRs are common drug targets," he said. "Since they are known to be very important in cell-environment interactions, they're very important in respect to disease pathology. In that respect, we now have a pathway into interrogating what those GPCRs actually respond to. You can imagine building a chip with many of these devices, each with different GPCRs, and exposing them all at once to various drugs to see which is effective at triggering a response."

Figuring out what kinds of drugs bind most effectively to GPCRs is important because pathogens often attack through those receptors as well. The better a harmless chemical attaches to a relevant GPCR, the better it is at blocking the disease.

The Penn team also made a technical advancement in stabilizing GPCRs for future research.

"In the past, if you take a protein out of a cell and put it onto a device, it might last for a day. But here, we embedded it in a nanoscale artificial cell membrane, which is called a nanodisc," Johnson said. "When we did that, they lasted for two and half months, instead of a day."

Increasing the lifespans of such devices could be beneficial to t
'/>"/>

Contact: Evan Lerner
elerner@upenn.edu
215-573-6604
University of Pennsylvania
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. U of M researchers may have discovered key to help women fight infections during pregnancy
2. Behavior 2011 to draw global contingent of more than 1,100 animal researchers to IU next week
3. U of M researchers discover gene required to maintain male sex throughout life
4. Caltech researchers create the first artificial neural network out of DNA
5. Western researchers receive $600,000 to study Prion diseases and Alzheimers
6. Researchers find potential key for unlocking biomass energy
7. Researchers present new trends in HIV cure research, call for proactive outreach programs to prevent HIV transmission in injecting drug users, and demand increased commitments to improving maternal and child health
8. E-health records should play bigger role in patient safety initiatives, researchers advocate
9. John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting
10. Researchers provide means of monitoring cellular interactions
11. USC researchers explore the source of empathy in the brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... of Arizona and Columbia University have discovered that tiny ... forces far stronger than experts had previously thought possible. ... a member of the BIO5 Institute and the department ... Type IV pili or filaments on the ...
... pathways that allow an errant gene to turn a cell ... single enzyme called the p21-activated kinase 1, or PAK1. ... a molecule capable of shutting down PAK1 before the enzyme ... breast cancer and have shown the enzyme is important in ...
... spacecraft SOHO shows clearly that powerful starquakes ripple around the ... above its surface. The observations give solar physicists new insight ... way of studying other stars. The outermost quarter of ... gas. Turbulence in this region causes ripples that criss-cross the ...
Cached Biology News:University of Arizona scientist shares in discovery of microbe filaments' power 2Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme 2Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme 3Solar flares set the Sun quaking 2
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
(Date:9/2/2015)... 2015 Aytu BioScience, Inc. (OTCQB: AYTU), a ... and related conditions, announced today that it has closed ... note financing, raising a total of $5.175 million, which ... Josh Disbrow , Chief Executive ... are intended to be used to conduct clinical studies ...
(Date:9/2/2015)... ... September 02, 2015 , ... Advancing in medical ... From vital sign monitoring in ICU to 3D skull printing analysis for Neurosurgery, ... real-time clinical decisions with simultaneous access to high precision medical images and electronic ...
(Date:9/1/2015)... Swecure, ein Biotechnologieunternehmen, ... Entwicklung neuartiger Therapien für Störungen des Immunsystems ... konzentriert, erhält vom US Patent and Trademark ... patentiert wird. Das Medikament basiert auf einem ... und Entzündungen vorbeugt.   Das Medikament, ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... 26, 2009): An experimental drug, LX211 (LUVENIQ; oral voclosporin), ... modifying the course of uveitis, a group of serious ... or substantial morbidity from steroid use. Results of international ... be the subject of two podium presentations at the ...
... CRANBURY, N.J., Oct. 29 Amicus Therapeutics (Nasdaq: ... quarter 2009. Additionally, Amicus also today announced that ... from its partner, Shire, for its lead lysosomal storage ... termination of their collaboration. The Company also announced ...
... BioSciences Inc. (NYSE Amex: YMI ; TSX: YM), ... advances a diverse portfolio of promising cancer-related products at ... a completed phase III study of nimotuzumab in children ... the preliminary data at ASCO 2008 were presented by ...
Cached Biology Technology:LX211 highlighted as potential disease modifying therapy for noninfectious uveitis 2LX211 highlighted as potential disease modifying therapy for noninfectious uveitis 3Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 2Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 3Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 4Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 5Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 6Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 7Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 8Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 9Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 10Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 11Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 12Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates 13YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 2YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 3YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG 4
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Yersinia pestis...
... features we add to WinList come straight ... every day. Features like automatic region positioning, ... result of good suggestions, thoughtful conversations, and ... features you depend on are still there, ...
Biology Products: